Validation of a short questionnaire to measure symptoms and functional limitations associated with hand‐foot syndrome and mucositis in patients with metastatic renal cell carcinoma

The HAMSIQ is a feasible, valid, reliable, and responsive instrument for assessing the impact of hand-foot syndrome and mucositis in patients receiving tyrosine kinase inhibitors. Cancer 2016;122:287-295. © 2015 American Cancer Society.